Advertisement

Topics

Molecular Insight Pharmaceuticals Company Profile

08:16 EDT 25th June 2018 | BioPortfolio

Molecular Insight Pharmaceuticals, Inc. is focused on the research, development and commercialization of innovative molecular imaging pharmaceuticals and targeted radiotherapeutics to diagnose, treat and manage disease. The company's two lead compounds, Zemivaâ„¢ and Azedraâ„¢, are in advancing clinical programs. Molecular Insight has completed a Phase 2b clinical trial for its lead cardiology product candidate, Zemivaâ„¢ (Iodofiltic acid I 123, also known as BMIPP) and intends to begin a pivotal registration trial for Zemivaâ„¢ in the second half of 2006. Zemivaâ„¢ is a molecular imaging pharmaceutical in later stage clinical development for its first targeted indication to rapidly diagnose cardiac ischemia, or insufficient blood flow to the heart, in chest pain patients in the hospital emergency department setting. Approximately five to eight million patients in the United States present to emergency departments each year complaining of chest pain. Molecular Insight Pharmceuticals' lead oncology product candidate is a radiotherapeutic for cancer, Azedraâ„¢ (Ultratraceâ„¢ MIBG), an FDA-designated Orphan Drug with a Fast Track designation to treat metastatic neuroendocrine tumors. The company also has molecular imaging programs in cardiology, oncology and neurology. Molecular Insight's pipeline leverages proprietary technologies to target, visualize, treat and monitor disease.

Location

160 Second Street
Cambridge
Massachusetts
02142
United States of America

Contact

Phone: 617.492.5554
Fax: 617.492.5664
Email: info@molecularinsight.com


News Articles [1049 Associated News Articles listed on BioPortfolio]

Molecular Templates reverse merges with Threshold Pharmaceuticals

Molecular Templates Inc. and Threshold Pharmaceuticals Inc. have reversed merged to form a new entity, which will take the Molecular Templates name and focus on continued development of two key cancer...

Studies provide insight into molecular changes prior to onset of arthritis

The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR 2018) provide insight into molecular changes prior to the onset of arthritis which could inform future...

Molecular Templates closes $40mm PIPE following reverse merger

Oncology firm Molecular Templates Inc. grossed $40mm through a private placement of 5.8mm units priced at $6.90. Each unit was comprised of one common share and a warrant to purchase 0.50 shares of co...

New insight into the molecular weapons of the plant microbiome

(American Society for Biochemistry and Molecular Biology) In a study published in the Feb. 2 issue of the Journal of Biological Chemistry, researchers at McMaster University in Canada pinpointed the i...

Global Molecular Diagnostic Testing Market 2016-2021 - Expected High Growth in Molecular ...

Molecular testing provides fast and accurate results and the prescence of molecular tests has disrupted several testing markets over the past decade and a half. Read more...

The Molecular Autopsy: Not Ready Yet for Prime Time

Although I have always been a strong advocate for sophisticated molecular and genomic testing, I tend to get a severe case of indigestion when I see references to the molecular autopsy (see: Can Inter...

Molecular Health introduces MH Mendel to help geneticists in diagnosing hereditary diseases

Molecular Health, a leading biomedical company that is transforming molecular data into clinically actionable information for efficient and safer cancer treatment options based on its proprietary Data...

Emerald Health Pharmaceuticals Inc.: Emerald Health Pharmaceuticals' Scientific Team Publishes Evidence of Neuroprotection Using Patented Cannabinoid Derivative for Parkinson's Disease

Study Published in Journal of Neuroinflammation Indicates the Potential of EHP-102, a New Molecular Entity Derived from Cannabigerol, to Provide Anti-Inflammatory and Neuroprotective Properties SAN...

PubMed Articles [1277 Associated PubMed Articles listed on BioPortfolio]

Impact of Pharmaceuticals on the Environment: Risk Assessment Using QSAR Modeling Approach.

An extensive use of pharmaceuticals and the widespread practices of their erroneous disposal measures have made these products contaminants of emerging concern (CEC). Especially, active pharmaceutical...

π-Cation Interactions in Molecular Recognition: Perspectives on Pharmaceuticals and Pesticides.

The π-cation interaction that differs from the cation-π interaction is a valuable concept in molecular design of pharmaceuticals and pesticides. In this Perspective we present an up-to-date review (...

Surfactants as Stabilizers for Biopharmaceuticals: An Insight into the Molecular Mechanisms for Inhibition of Protein Aggregation.

Surfactants are common stabilizers, often added to biopharmaceuticals formulations, but the mechanisms at the basis of their activity are unclear. The aim of this work is to provide insight into the m...

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

ECOdrug: a database connecting drugs and conservation of their targets across species.

Pharmaceuticals are designed to interact with specific molecular targets in humans and these targets generally have orthologs in other species. This provides opportunities for the drug discovery commu...

Clinical Trials [1801 Associated Clinical Trials listed on BioPortfolio]

Role of IL-37 Genetic Variants in Modulating Innate Immune Response to Periodontal Pathogens

This study will provide mechanistic insight into the underlying causes and molecular level pathogenesis of periodontal diseases. We will identify key mechanisms that confer risk and protec...

Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic 20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sepa...

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic®20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sep...

Cognate Patient Care Insight Scale

Schizophrenia is a disease of young adults that affects 1% of the general population. According to numerous studies, it has been estimated that between 50% and 80% of patients with schizop...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Companies [2398 Associated Companies listed on BioPortfolio]

Molecular Insight Pharmaceuticals

Molecular Insight Pharmaceuticals, Inc. is focused on the research, development and commercialization of innovative molecular imaging pharmaceuticals and targeted radiotherapeutics to diagnose, treat ...

Insight Pharmaceuticals Corp.

Insight Pharmaceuticals was founded to acquire niche consumer OTC drug products from larger companies, focusing on their biggest brands. The company's philosophy is to earn custom...

Insight Pharmaceuticals

Headquartered in Langhorne, PA, Insight Pharmaceuticals was founded in 1997 as a manufacturer and marketer of niche consumer over-the-counter medications that aid users in managing common ailments. Th...

Insight Genetics

Insight Genetics is a molecular diagnostics company focused on enhancing personalized cancer care. The company’s companion diagnostics detect specific cancer biomarkers relat...

Insight Genetics, Inc.

Insight Genetics is dedicated to improving the lives of cancer patients through advanced molecular diagnostics that enable precision in cancer care. The company specializes in the...

More Information about "Molecular Insight Pharmaceuticals" on BioPortfolio

We have published hundreds of Molecular Insight Pharmaceuticals news stories on BioPortfolio along with dozens of Molecular Insight Pharmaceuticals Clinical Trials and PubMed Articles about Molecular Insight Pharmaceuticals for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Molecular Insight Pharmaceuticals Companies in our database. You can also find out about relevant Molecular Insight Pharmaceuticals Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...


Corporate Database Quicklinks



Searches Linking to this Company Record